Fourth Compound from S*BIO, Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory …

Published November 23, 2010

Fourth Compound from S*BIO, Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory …
S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO’s oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO’s development and commercialization partner for the program …
Read more on PR Newswire via Yahoo! Finance

Boston Scientific Investor Day – Transcript
Courtesy of Seeking AlphaBoston Scientific Corporation (BSX) Investor Day Conference Call November 1…
Read more on citybizlist Boston

Hearing to resume for detox facility
A controversial application to locate a drug detoxification center in a vacant office building at 100 Federal City Road drew a standing-room-only crowd at the Zoning Board of Adjustmentâs public hearing last week.
Read more on The Lawrence Ledger